SoftBank's $5.8B Withdrawal Raises Questions About AI Growth, Causing Nvidia Stock to Tumble
- SoftBank's $5.8B sale of its Nvidia stake triggered a 3.1% stock drop on Nov 11, 2025, signaling investor doubts about AI sector momentum. - The sell-off coincided with U.S. export restrictions to China, HBM supply delays, and AMD's $1T data-center market projections challenging Nvidia's dominance. - Analysts raised price targets to $230-$265 based on strong GB200 demand, but broader tech market declines highlighted risks in stretched AI valuations. - Upcoming Nov 19 earnings will test Nvidia's ability t
On November 11, 2025, Nvidia's stock experienced a significant drop after SoftBank Group sold its entire $5.8 billion holding in the AI chip giant, causing turbulence across the tech industry. The Japanese conglomerate's full divestment, revealed in late October, sparked speculation about whether its once-bold commitment to artificial intelligence was waning.
This downturn continued a trend of volatility for
Even with these short-term headwinds, analysts remain guardedly positive. Rick Schafer of Oppenheimer increased his Nvidia price target to $265 from $225, while Christopher Rolland at Susquehanna maintained a $230 target, citing robust demand for Nvidia's GB200 AI products
Investors are looking to Nvidia's November 19 earnings release for further insight. The company will need to prove ongoing demand for its Blackwell chips and address ongoing supply issues,
---
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
ALGO experienced a 16.57% quarter-over-quarter decline due to product transitions and fluctuations in the market.
- ALGO fell 16.57% QoQ amid market volatility and product transition challenges at Alargo. - Alargo replaced Akaroid with NHD, achieving 80% YoY sales growth through direct doctor engagement. - AXI's margin optimization doubled contribution per piece despite 60% volume decline from low-margin delistings. - ARCO Pharma's rebranding and scientific training aims to strengthen pharmacist relationships and market position. - Analysts note long-term margin potential but warn of short-term revenue risks from tran
BCH Drops 1.35% Today as Loan Expansion Slows and Profitability Faces Challenges
- BCH fell 1.35% in 24 hours amid weak loan growth and reduced inflation adjustment income, with 60% revenue tied to net interest income. - Institutional holdings rose 12.75% but shares held dropped 3.53%, as Bridge Builder increased exposure while Baillie Gifford cut holdings by 289.93%. - Goldman Sachs maintains Neutral rating with 0.70% upside, while backtesting shows mixed post-earnings performance with limited statistical significance from two data points.
ZEC drops 5.9% over 24 hours as significant institutional funds flow in
- Zcash (ZEC) fell 5.9% in 24 hours amid a 20.64% 7-day drop, but gained 768.62% over one year. - Cypherpunk Technologies acquired 1.25% of ZEC supply via a $58.88M Winklevoss Capital-backed investment, aiming to accumulate 5% total supply. - Tyler Winklevoss positioned Zcash as "encrypted Bitcoin ," emphasizing privacy-driven value transfer and potential to capture Bitcoin's market share. - Technical analysis shows ZEC breaking key support levels with RSI near neutrality, while institutional activity reve
LUNA Drops 2.7% Over 24 Hours as Overall Market Shows Signs of Weakness
- LUNA fell 2.7% in 24 hours to $0.0788, continuing a 12.29% weekly and 15.2% monthly decline. - Technical indicators show bearish momentum, with RSI below key support and MACD in negative territory. - The drop reflects broader market caution and waning investor confidence amid persistent risk-off behavior.